Comparing the effects of Shallomin and Podophyllin solution 25% in treatment of genital HPV warts in wome
Not Applicable
Recruiting
- Conditions
- Genital warts.Anogenital (venereal) warts
- Registration Number
- IRCT2017011531949N1
- Lead Sponsor
- Vice chancellor for research, Ahvaz Jundishapur University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
genital HPV warts under 2cm
exclusion criteria:age under 15; breast feeding; pregnancy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tratment of genital warts. Timepoint: 6 week later. Method of measurement: Visit with dermatologist.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Shallomin's antiviral activity against HPV in genital warts?
How does Shallomin compare to 25% Podophyllin solution in treating anogenital warts in women?
Are there specific biomarkers that predict response to Shallomin in HPV-infected patients?
What are the potential adverse events associated with Shallomin versus Podophyllin in genital wart treatment?
What are related compounds or combination therapies for HPV warts beyond Shallomin and Podophyllin?